Semler Reports Third Quarter and Year-to-Date 2021 Financial Results
Semler Scientific (SMLR) reported strong financial results for Q3 and nine months ending September 30, 2021. Revenues reached $14.0 million, a 30% increase year-over-year, with a pre-tax net income of $5.3 million, down 6% compared to last year. For the nine months, revenues surged 56% to $41.5 million, with total net income rising 82% to $15.7 million. Despite a sequential decline in fee-per-test revenue attributed to the Delta variant, the company remains profitable and expects ongoing revenue growth. Cash reserves improved to $35.9 million.
- Q3 revenues increased by $3.3 million (30%) year-over-year.
- Nine-month revenues up $15.0 million (56%) year-over-year.
- Net income for nine months rose by $7.1 million (82%).
- Cash and cash equivalents increased to $35.9 million.
- Sequential decline in fee-per-test revenue in Q3.
- Pre-tax net income decreased by $0.3 million (6%) in Q3.
SANTA CLARA, Calif., Nov. 1, 2021 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today reported financial results for the three and nine months ended September 30, 2021.
"Revenues and earnings continued to be strong compared to last year," said Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific. "We did experience a sequential decline in fee-per-test revenue for the third quarter compared to the second quarter. We believe this change may be due in part to the Delta variant and to some level of seasonality."
FINANCIAL RESULTS
For the quarter ended September 30, 2021, compared to the corresponding period of 2020, Semler Scientific reported:
- Revenues of
$14.0 million , an increase of$3.3 million , or30% , compared to$10.7 million - Cost of revenues of
$1.4 million , an increase of$0.6 million , or69% , compared to$0.8 million . As a percentage of revenues, cost of revenues was10% , compared to8% - Total operating expenses, which includes cost of revenues, of
$8.7 million , an increase of$3.5 million , or69% , compared to$5.2 million - Pre-tax net income of
$5.3 million , a decrease of$0.3 million , or6% , or$0.78 per basic share and$0.65 per diluted share, compared to$5.6 million , or$0.85 per basic share and$0.70 per diluted share - Net income of
$4.2 million , or$0.61 per basic share and$0.51 per diluted share, a decrease of$0.7 million , or15% , compared to$4.9 million , or$0.74 per basic share and$0.61 per diluted share. As a percentage of revenues, net income was30% compared to45%
For the nine months ended September 30, 2021, compared to the corresponding period of 2020, Semler Scientific reported:
- Revenues of
$41.5 million , an increase of$15.0 million , or56% , compared to$26.5 million - Cost of revenues of
$4.0 million , an increase of$1.6 million , or67% , compared to$2.4 million . As a percentage of revenues, cost of revenues was10% , compared to9% - Total operating expenses, which includes cost of revenues, of
$23.8 million , an increase of$7.2 million , or43% , compared to$16.6 million - Pre-tax net income of
$17.7 million , or$2.64 per basic share and$2.18 per diluted share an increase of$7.7 million , or77% , compared to$10.0 million , or$1.53 per basic share and$1.25 per diluted share - Net income of
$15.7 million , or$2.34 per basic share and$1.93 per diluted share, an increase of$7.1 million , or82% , compared to$8.6 million , or$1.31 per basic share and$1.07 per diluted share. As a percentage of revenues, net income was38% compared to32%
Semler Scientific had cash and cash equivalents of
THIRD QUARTER 2021 MAJOR ACCOMPLISHMENTS AND OTHER DETAILS
Among the achievements during the third quarter of 2021 were:
- Consecutive quarterly profitability since the fourth quarter of 2017.
- Cash and cash equivalents position increased to
$35.9 million . - Relisted common stock on the Nasdaq Capital Market.
In the third quarter of 2021 compared to the corresponding period of 2020, fixed fee license revenues were approximately
Semler Scientific's two largest customers comprised
For the nine months ended September 30, 2021 compared to the corresponding period of 2020, fixed fee software license revenues were approximately
For the nine months ended September 30, 2021, Semler Scientific's two largest customers comprised
Variable fee license revenues (that is, fee-per-test), which had rebounded strongly in the first half of 2021 from the effects of the COVID-19 pandemic in 2020, did decrease sequentially in the third quarter of 2021 compared to the second quarter of 2021. Semler Scientific believes this may be either due to effects of the Delta variant of COVID-19 during the third quarter of 2021, or due to a new seasonality in the home-testing market, which it hasn't seen in prior periods, or due to both.
For the remainder of 2021 and in 2022, Semler Scientific expects continued profitability and generation of cash from operating activities. It is Semler Scientific's intent to grow annual revenues at a faster rate than annual expenses and to remain profitable.
Notice of Conference Call
Semler Scientific will host a conference call today at 4:30 p.m. ET. The call will address results of the third quarter and first nine months of 2021 as well as provide a business update on Semler Scientific's market outlook and strategies for the near-term future.
Participants are encouraged to pre-register for the conference call using the following link: https://dpregister.com/sreg/10160155/ed3c71410a. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those without internet access or who are unable to pre-register may dial in by calling:
Domestic callers: (866) 777–2509
International callers: (412) 317–5413
Please specify to the operator that you would like to join the "Semler Scientific Call." The conference call will be archived on Semler Scientific's website at www.semlerscientific.com.
Semler Scientific, Inc. Statements of Income Unaudited | |||||||||||||
(In thousands of U.S. Dollars, except for share and per share data) | |||||||||||||
For the three months ended September 30, | For the nine months ended September 30, | ||||||||||||
2021 | 2020 | 2021 | 2020 | ||||||||||
Revenues | $ | 13,991 | $ | 10,727 | $ | 41,485 | $ | 26,530 | |||||
Operating expenses: | |||||||||||||
Cost of revenues | 1,382 | 820 | 3,957 | 2,370 | |||||||||
Engineering and product development | 1,036 | 672 | 2,676 | 2,277 | |||||||||
Sales and marketing | 3,968 | 2,116 | 10,407 | 7,283 | |||||||||
General and administrative | 2,352 | 1,564 | 6,710 | 4,634 | |||||||||
Total operating expenses | 8,738 | 5,172 | 23,750 | 16,564 | |||||||||
Income from operations | 5,253 | 5,555 | 17,735 | 9,966 | |||||||||
Interest income | 3 | 2 | 8 | 5 | |||||||||
Other income | 1 | 38 | 6 | 64 | |||||||||
Other income | 4 | 40 | 14 | 69 | |||||||||
Pre-tax net income | 5,257 | 5,595 | 17,749 | 10,035 | |||||||||
Income tax provision | 1,107 | 729 | 2,034 | 1,421 | |||||||||
Net income | $ | 4,150 | $ | 4,866 | $ | 15,715 | $ | 8,614 | |||||
Net income per share, basic | $ | 0.61 | $ | 0.74 | $ | 2.34 | $ | 1.31 | |||||
Weighted average number of shares used in computing basic income per share | 6,754,526 | 6,578,808 | 6,722,858 | 6,553,522 | |||||||||
Net income per share, diluted | $ | 0.51 | $ | 0.61 | $ | 1.93 | $ | 1.07 | |||||
Weighted average number of shares used in computing diluted income per share | 8,143,377 | 8,038,513 | 8,135,337 | 8,046,759 | |||||||||
Semler Scientific, Inc. Condensed Balance Sheets | ||||||
(In thousands of U.S. Dollars) | ||||||
At September 30, | At December 31, | |||||
2021 | 2020 | |||||
Unaudited | ||||||
Cash and cash equivalents | $ | 35,930 | $ | 22,079 | ||
Other current assets | 10,165 | 4,524 | ||||
Noncurrent assets | 4,878 | 8,036 | ||||
Total assets | 50,973 | 34,639 | ||||
Current liabilities | 6,693 | 4,514 | ||||
Noncurrent liabilities | 266 | 332 | ||||
Stockholders' equity | 44,014 | 29,793 | ||||
Total liabilities and stockholders' equity | $ | 50,973 | $ | 34,639 | ||
About Semler Scientific, Inc.:
Semler Scientific, Inc. is a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. Semler Scientific's mission is to develop, manufacture and market innovative products and services that assist its customers in evaluating and treating chronic diseases. Semler Scientific commercially launched its first patented and U.S. Food and Drug Administration, or FDA, cleared product in 2011, and received FDA 510(k) clearance for QuantaFlo®, the next generation version of this product, in 2015. QuantaFlo® is a rapid point-of-care test that measures arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease. QuantaFlo® is used by Semler Scientific's customers to more comprehensively evaluate their patients for risk of heart attacks and strokes. Semler Scientific believes it is positioned to provide valuable information to its insurance company and physician customers, which in turn permits them to better guide patient care. Additional information about Semler Scientific can be found at semlerscientific.com.
Forward-Looking Statements
This press release contains "forward-looking" statements. Such statements can be identified by, among other things, the use of forward-looking language such as the words "may," "will," "intend," "expect," "anticipate," "estimate," "project," "would," "could" or words with similar meaning or the negatives of these terms or by the discussion of strategy or intentions. The forward-looking statements in this release include statements regarding Semler Scientific's continued profitability and cash generation from operations, as well as the relative rate of revenue and expenses growth and ability to remain profitable. Such forward-looking statements are subject to a number of risks and uncertainties that could cause Semler Scientific's actual results to differ materially from those discussed here, such as whether or not insurance plans and other customers will continue to license its cardiovascular testing products, whether or not it will be able to successfully expand its product offering, and its ability to continue to control expenses and preserve cash, as well as uncertainty created by COVID–19, along with those risk factors detailed in Semler Scientific's SEC filings. These forward-looking statements involve assumptions, estimates, and uncertainties that reflect current internal projections, expectations or beliefs. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. All forward-looking statements contained in this press release are qualified in their entirety by these cautionary statements and the risk factors described above. Furthermore, all such statements are made as of the date of this release and Semler Scientific assumes no obligation to update or revise these statements unless otherwise required by law.
INVESTOR CONTACT:
Susan A. Noonan
S.A. Noonan Communications
susan@sanoonan.com
917 513 5303
View original content:https://www.prnewswire.com/news-releases/semler-reports-third-quarter-and-year-to-date-2021-financial-results-301413122.html
SOURCE Semler Scientific, Inc.
FAQ
What were Semler Scientific's Q3 2021 earnings results?
How did Semler Scientific perform in the nine months ended September 30, 2021?
What factors contributed to the decline in fee-per-test revenue for Semler Scientific?
What is the outlook for Semler Scientific for the remainder of 2021 and 2022?
